$0.72
8.19% yesterday
Nasdaq, Nov 12, 10:17 pm CET
ISIN
US0021201035
Symbol
ATYR

aTyr Pharma, Inc. Stock price

$0.72
-0.24 25.16% 1M
-2.52 77.69% 6M
-2.90 80.03% YTD
-2.77 79.29% 1Y
-1.71 70.26% 3Y
-2.64 78.49% 5Y
-137.32 99.48% 10Y
-208.58 99.65% 20Y
Nasdaq, Closing price Wed, Nov 12 2025
-0.06 8.19%
ISIN
US0021201035
Symbol
ATYR
Industry

Key metrics

Basic
Market capitalization
$70.8m
Enterprise Value
$-18.4m
Net debt
positive
Cash
$90.2m
Shares outstanding
98.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
372.8 | 57.9
EV/Sales
negative | negative
EV/FCF
0.3
P/B
0.9
Financial Health
Equity Ratio
72.3%
Return on Equity
-91.4%
ROCE
-86.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$190.0k | $1.2m
EBITDA
$-79.0m | $-72.8m
EBIT
$-78.7m | $-76.2m
Net Income
$-75.1m | $-73.5m
Free Cash Flow
$-63.0m
Growth (TTM | estimate)
Revenue
-20.8% | 410.0%
EBITDA
-19.1% | -8.3%
EBIT
-15.6% | -12.2%
Net Income
-17.7% | -14.8%
Free Cash Flow
6.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-41,571.6% | -5,945.8%
EBIT
-41,395.3%
Net
-39,537.9% | -6,001.9%
Free Cash Flow
-33,154.2%
More
EPS
$-0.8
FCF per Share
$-0.6
Short interest
37.9%
Employees
-
Rev per Employee
-
Show more

Is aTyr Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

aTyr Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a aTyr Pharma, Inc. forecast:

9x Buy
53%
8x Hold
47%

Analyst Opinions

17 Analysts have issued a aTyr Pharma, Inc. forecast:

Buy
53%
Hold
47%

Financial data from aTyr Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.19 0.19
21% 21%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
29% 29%
9,100%
- Research and Development Expense 62 62
12% 12%
32,400%
-79 -79
19% 19%
-41,574%
- Depreciation and Amortization -0.34 -0.34
120% 120%
-179%
EBIT (Operating Income) EBIT -79 -79
16% 16%
-41,395%
Net Profit -75 -75
18% 18%
-39,537%

In millions USD.

Don't miss a Thing! We will send you all news about aTyr Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

aTyr Pharma, Inc. Stock News

Neutral
GlobeNewsWire
about 15 hours ago
SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation.
Neutral
PRNewsWire
about 19 hours ago
LOS ANGELES , Nov. 12, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR). IF YOU SUFFERED A LOSS ON YOUR ATYR INVESTMENTS, CLICK HERE BEFORE DECEMBER 8, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSU...
Neutral
PRNewsWire
2 days ago
ATYR Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Nov. 11, 2025 /PRNewswire/ -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The firm urges investors in aTyr who suffered significant losses to submit you...
More aTyr Pharma, Inc. News

Company Profile

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Sanjay Shukla
Founded 2005
Website www.atyrpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today